These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36089786)

  • 1. Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19.
    Tsagkaris C; Bilal M; Aktar I; Aboufandi Y; Tas A; Aborode AT; Suvvari TK; Ahmad S; Shkodina A; Phadke R; Emhamed MS; Baig AA; Alexiou A; Ashraf GM; Kamal MA
    Curr Alzheimer Res; 2022; 19(9):641-657. PubMed ID: 36089786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses.
    Pilotto A; Masciocchi S; Volonghi I; De Giuli V; Caprioli F; Mariotto S; Ferrari S; Bozzetti S; Imarisio A; Risi B; Premi E; Benussi A; Focà E; Castelli F; Zanusso G; Monaco S; Stefanelli P; Gasparotti R; Zekeridou A; McKeon A; Ashton NJ; BlennoW K; Zetterberg H; Padovani A
    Clin Infect Dis; 2021 Nov; 73(9):e3019-e3026. PubMed ID: 33395482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome.
    Guasp M; Muñoz-Sánchez G; Martínez-Hernández E; Santana D; Carbayo Á; Naranjo L; Bolós U; Framil M; Saiz A; Balasa M; Ruiz-García R; Sánchez-Valle R;
    Front Immunol; 2022; 13():866153. PubMed ID: 35479062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm.
    Garcia MA; Barreras PV; Lewis A; Pinilla G; Sokoll LJ; Kickler T; Mostafa H; Caturegli M; Moghekar A; Fitzgerald KC; ; Pardo CA
    J Neurol Sci; 2021 Aug; 427():117517. PubMed ID: 34090021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity.
    Virhammar J; Nääs A; Fällmar D; Cunningham JL; Klang A; Ashton NJ; Jackmann S; Westman G; Frithiof R; Blennow K; Zetterberg H; Kumlien E; Rostami E
    Eur J Neurol; 2021 Oct; 28(10):3324-3331. PubMed ID: 33369818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Paradox of COVID-19 in Neurological Complications with Emphasis on Parkinson's and Alzheimer's Disease.
    Rai SN; Tiwari N; Singh P; Singh AK; Mishra D; Imran M; Singh S; Hooshmandi E; Vamanu E; Singh SK; Singh MP
    Oxid Med Cell Longev; 2022; 2022():3012778. PubMed ID: 36092161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
    Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
    Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helminth alleviates COVID-19-related cytokine storm in an IL-9-dependent way.
    Cao Z; Wang J; Liu X; Liu Y; Li F; Liu M; Chiu S; Jin X
    mBio; 2024 Jun; 15(6):e0090524. PubMed ID: 38727220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Levels of NfL, GFAP, TAU, and UCH-L1 as Potential Predictor Biomarkers of Severity and Lethality in Acute COVID-19.
    Salvio AL; Fernandes RA; Ferreira HFA; Duarte LA; Gutman EG; Raposo-Vedovi JV; Filho CHFR; da Costa Nunes Pimentel Coelho WL; Passos GF; Andraus MEC; da Costa Gonçalves JP; Cavalcanti MG; Amaro MP; Kader R; de Andrade Medronho R; Figueiredo CP; Amado-Leon LA; Alves-Leon SV
    Mol Neurobiol; 2024 Jun; 61(6):3545-3558. PubMed ID: 37996731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases.
    Park Y; Kc N; Paneque A; Cole PD
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia.
    Barbieri MA; Bagnato G; Ioppolo C; Versace AG; Irrera N
    CNS Neurol Disord Drug Targets; 2022; 21(10):1017-1026. PubMed ID: 35021982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
    Wang J; Jiang M; Chen X; Montaner LJ
    J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
    Ramasamy S; Subbian S
    Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
    Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
    J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes.
    Lennol MP; Ashton NJ; Moreno-Pérez O; García-Ayllón MS; Ramos-Rincon JM; Andrés M; León-Ramírez JM; Boix V; Gil J; Blennow K; Merino E; Zetterberg H; Sáez-Valero J
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine/Chemokine Expression Is Closely Associated Disease Severity of Human Adenovirus Infections in Immunocompetent Adults and Predicts Disease Progression.
    Li J; Wei J; Xu Z; Jiang C; Li M; Chen J; Li Y; Yang M; Gu Y; Wang F; Shu Y; Yang Y; Sun L; Liu Y
    Front Immunol; 2021; 12():691879. PubMed ID: 34163488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation.
    Garcia MA; Barreras PV; Lewis A; Pinilla G; Sokoll LJ; Kickler T; Mostafa H; Caturegli M; Moghekar A; Fitzgerald KC; Pardo CA
    medRxiv; 2021 Jan; ():. PubMed ID: 33469596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible mechanism of central nervous system targeting and neurological symptoms of the new-coronavirus (COVID-19): literature review.
    Jumagaliyeva M; Ayaganov D; Saparbayev S; Tuychibaeva N; Abdelazim IA; Kurmambayev Y; Khamidullina Z; Yessenamanova S
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9420-9428. PubMed ID: 37843354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.